{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:31:31Z","timestamp":1770748291622,"version":"3.49.0"},"reference-count":161,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Kidneys are responsible for many crucial biological processes in the human body, including maintaining the water\u2013electrolyte balance, pH, and blood pressure (BP), along with the elimination of toxins. Despite this, chronic kidney disease (CKD), which affects more and more people, is a disease that develops insidiously without causing any symptoms at first. The main purpose of this article is to summarize the existing literature on lercanidipine, with a particular focus on its nephroprotective properties. Lercanidipine is a third-generation dihydropyridine (DHP) blocker of calcium channels, and as such it possesses unique qualities such as high lipophilicity and high vascular selectivity. Furthermore, it acts by reversibly inhibiting L-type and T-type calcium channels responsible for exerting positive renal effects. It has been shown to reduce tissue inflammation and tubulointerstitial fibrosis, contributing to a decrease in proteinuria. Moreover, it exhibited antioxidative effects and increased expression of molecules responsible for repairing damaged tissues. It also decreased cell proliferation, preventing thickening of the vascular lumen. This article summarizes studies simultaneously comparing the effect of lercanidipine with other antihypertensive drugs. There is still a lack of studies on the medications used in patients with CKD, and an even greater lack of studies on those used in patients with concomitant hypertension. Therefore, further studies on lercanidipine and its potential in hypertensive patients with coexisting CKD are required.<\/jats:p>","DOI":"10.3390\/ijms241814048","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:57:56Z","timestamp":1694685476000},"page":"14048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Insights into the Nephroprotective Potential of Lercanidipine"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6892-6199","authenticated-orcid":false,"given":"Joanna","family":"Hajdys","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7469-7056","authenticated-orcid":false,"given":"Piotr","family":"Fularski","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6985-7008","authenticated-orcid":false,"given":"Klaudia","family":"Leszto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0447-8510","authenticated-orcid":false,"given":"Gabriela","family":"Majchrowicz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Stabrawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-4746","authenticated-orcid":false,"given":"Ewelina","family":"M\u0142ynarska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. \u017beromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cca.2019.08.030","article-title":"Chronic kidney disease: Biomarker diagnosis to therapeutic targets","volume":"499","author":"Wang","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pop.2020.08.001","article-title":"Chronic Kidney Disease","volume":"47","author":"Charles","year":"2020","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Naber, T., and Purohit, S. (2021). Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients, 13.","DOI":"10.20944\/preprints202106.0233.v1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1590\/1806-9282.66.s1.3","article-title":"Chronic Kidney Disease","volume":"66","author":"Ammirati","year":"2020","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/2175-8239-jbn-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"Lucas","year":"2019","journal-title":"J. Bras. Nefrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"822870","DOI":"10.3389\/fmed.2022.822870","article-title":"Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition","volume":"9","author":"Baudoux","year":"2022","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: Core Curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1159\/000528560","article-title":"Cardiovascular Risk Prediction in Chronic Kidney Disease","volume":"53","author":"Li","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pcl.2018.09.007","article-title":"Chronic Kidney Disease and Dietary Measures to Improve Outcomes","volume":"66","author":"Akchurin","year":"2018","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_11","first-page":"7482","article-title":"Antihypertensive treatment with calcium channel blockers and renal protection: Focus on lercanidipine and lercanidipine\/enalapril","volume":"26","author":"Ferri","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/jpp.JPP_34_17","article-title":"Lercanidipine in the Management of Hypertension: An Update","volume":"8","author":"Grassi","year":"2017","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_13","first-page":"4025","article-title":"Lercanidipine and T-type calcium current","volume":"22","author":"Cerbai","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/13543784.8.7.1043","article-title":"Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity","volume":"8","author":"Meredith","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjp.0705786","article-title":"Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine","volume":"142","author":"Wirtz","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","first-page":"15","article-title":"Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine","volume":"46","author":"Guarneri","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00005344-199611000-00012","article-title":"Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes","volume":"28","author":"Corsini","year":"1996","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_18","first-page":"145","article-title":"Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs","volume":"46","author":"Sironi","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/00003495-200060050-00009","article-title":"Lercanidipine: A review of its use in hypertension","volume":"60","author":"McClellan","year":"2000","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2165\/00003495-200363220-00013","article-title":"Lercanidipine: A review of its efficacy in the management of hypertension","volume":"63","author":"Bang","year":"2003","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199729002-00002","article-title":"Clinical Pharmacokinetics of Lercanidipine","volume":"29","author":"Barchielli","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/17425250903085135","article-title":"Treatment of essential hypertension with calcium channel blockers: What is the place of lercanidipine?","volume":"5","author":"Burnier","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_23","first-page":"173","article-title":"Lercanidipine in hypertension","volume":"1","author":"Borghi","year":"2005","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_24","first-page":"155","article-title":"Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist","volume":"52","author":"Klotz","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/080370598438998","article-title":"Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties","volume":"2","author":"Herbette","year":"1998","journal-title":"Blood Press Suppl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1081\/JDI-42801","article-title":"Lercanidipine in patients with chronic renal failure: The ZAFRA study","volume":"27","author":"Robles","year":"2005","journal-title":"Ren Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jcph.1485","article-title":"Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients with Chronic Kidney Disease","volume":"60","author":"Schaab","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00005344-199729001-00003","article-title":"In Vitro Calcium Antagonist Activity of Lercanidipine and Its Enantiomers","volume":"29","author":"Leonardi","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shah, K., Seeley, S., Schulz, C., Fisher, J., and Rao, S.G. (2022). Calcium Channels in the Heart: Disease States and Drugs. Cells, 11.","DOI":"10.3390\/cells11060943"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1874467208666150507105845","article-title":"Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?","volume":"8","author":"Striessnig","year":"2015","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1093\/emboj\/cdg583","article-title":"Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation","volume":"22","author":"Moosmang","year":"2003","journal-title":"EMBO J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"H415","DOI":"10.1152\/ajpheart.01214.2005","article-title":"Role of Cav1.2 L-type Ca2+ channels in vascular tone: Effects of nifedipine and Mg2+","volume":"292","author":"Zhang","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1172\/JCI20208","article-title":"Isoform-specific regulation of mood behavior and pancreatic \u03b2 cell and cardiovascular function by L-type Ca2+ channels","volume":"113","author":"Hetzenauer","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03339863","article-title":"Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension","volume":"12","author":"Barbagallo","year":"2000","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0895-7061(03)00901-4","article-title":"Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension","volume":"16","author":"Fogari","year":"2003","journal-title":"Am. J. Hypertens."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0011-393X(00)80031-4","article-title":"Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: A randomized, double-blind pilot study","volume":"61","author":"Cavallini","year":"2000","journal-title":"Curr. Ther. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2302\/kjm.59.84","article-title":"T-Type Ca channel blockade as a determinant of kidney protection","volume":"59","author":"Hayashi","year":"2010","journal-title":"Keio J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/01.HYP.35.3.775","article-title":"Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats","volume":"35","author":"Sabbatini","year":"2000","journal-title":"Hypertension"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/sj.bjp.0702221","article-title":"Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits","volume":"125","author":"Soma","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00004872-200006001-00219","article-title":"Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients","volume":"18","author":"Fogari","year":"2000","journal-title":"J. Hypertens."},{"key":"ref_44","unstructured":"S\u00e0nchez, A., Sayans, R., and Alvarez, J.L. (1999, January 27\u201329). Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril. Proceedings of the 4th European Meeting on Calcium Antagonists, Amsterdam, The Netherlands."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1254\/jjp.80.199","article-title":"Therapeutic effects of a calcium antagonist, lacidipine, on stroke-prone spontaneously hypertensive rats with cerebrovascular lesions","volume":"80","author":"Funato","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4943(03)00047-5","article-title":"Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: The ELderly and LErcanidipine (ELLE) study","volume":"37","author":"Cherubini","year":"2003","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1524-6175.2003.01960.x","article-title":"Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study","volume":"5","author":"Romito","year":"2003","journal-title":"J. Clin. Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","article-title":"Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives","volume":"15","author":"Leonetti","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08037050211265","article-title":"Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study","volume":"11","author":"Barrios","year":"2002","journal-title":"Blood Press"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1517\/14656566.8.14.2215","article-title":"Efficacy and tolerability of lercanidipine in patients with hypertension: Results of a Phase IV study in general practice","volume":"8","author":"Burnier","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1527-3466.2007.00035.x","article-title":"Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: The TOLERANCE Study","volume":"26","author":"Barrios","year":"2008","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1742-1241.2006.01176.x","article-title":"Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA Study","volume":"60","author":"Barrios","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/00005344-199729002-00008","article-title":"Efficacy and Tolerability of Lercanidipine in Elderly Patients with Mild to Moderate Hypertension in a Placebo-Controlled, Double-Blind Study","volume":"29","author":"Ninci","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00005344-199729002-00004","article-title":"Active Dose Findings for Lercanidipine in a Double-Blind, Placebo-Controlled Design in Patients with Mild to Moderate Hypertension","volume":"29","author":"Circo","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00004872-199816120-00017","article-title":"Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements","volume":"16","author":"Omboni","year":"1998","journal-title":"J. Hypertens."},{"key":"ref_56","first-page":"23","article-title":"Efficacy and tolerability of lercanidipine once a day versus placebo in mild to moderate arterial hypertension","volume":"20","author":"Rimoldi","year":"1994","journal-title":"Acta Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/00005344-199729002-00010","article-title":"Lercanidipine in Two Different Dosage Regimens as a Sole Treatment for Severe Essential Hypertension","volume":"29","author":"Paterna","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_58","unstructured":"Silva, A. (2000). A Multicenter Randomized, Double-Blind Trial of the Efficacy and Safety of Lercanidipine in Patients with Mild to Moderate Essential Hypertension, Uncontrolled on Hydrochlorothiazide, Recordati. Clinical Study Report No. REC 15\/2375\u2212CLP2-0003."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2019-0008","article-title":"Current perspective on the use of calcium channel blockers to treat hypertensive patients: The role of lercanidipine","volume":"15","author":"Mancia","year":"2019","journal-title":"Future Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10641963.2011.601381","article-title":"Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice","volume":"34","author":"Cicero","year":"2011","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jchromb.2004.09.038","article-title":"Enantioselective pharmacokinetics of lercanidipine in healthy volunteers","volume":"813","author":"Jabor","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/VHRM.S91020","article-title":"Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: An update of the evidence","volume":"12","author":"Antza","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.colsurfb.2011.04.016","article-title":"Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system","volume":"86","author":"Parmar","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejpb.2016.04.001","article-title":"Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation","volume":"103","author":"Chonkar","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijbiomac.2014.08.017","article-title":"Dissolution and bioavailability of lercanidipine\u2013hydroxypropylmethyl cellulose nanoparticles with surfactant","volume":"72","author":"Ha","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.53738\/REVMED.2006.2.78.2047","article-title":"La lercanidipine, un inhibiteur calcique de troisi\u00e8me g\u00e9n\u00e9ration. Quels avantages?","volume":"78","author":"Meier","year":"2006","journal-title":"Rev. M\u00e9d. Suisse"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"58A","DOI":"10.1016\/S0895-7061(02)02424-X","article-title":"P-73: Observations on the safety of lercanidipine: Adverse event data from placebo-controlled trials","volume":"15","author":"Hollenberg","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2014.964855","article-title":"Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke","volume":"31","author":"Sinh","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_70","unstructured":"Rajesh, R. (2018). Formulation Development and Invitro Evaluation of Mouth Dissolving Tablets of Lercanidipine Hydrochloride by Direct Compression Method: An Approach to Improving Oral Bioavailibility, JKK Nattraja College of Pharmacy."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tecen-Yucel, K., Bayraktar-Ekincioglu, A., Y\u0131ld\u0131r\u0131m, T., Demirkan, K., and Erdem, Y. (Eur. J. Hosp. Pharm., 2023). Evaluation of drug interaction between cyclosporine and lercanidipine: A descriptive study, Eur. J. Hosp. Pharm., in press.","DOI":"10.1136\/ejhpharm-2023-003757"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"854015","DOI":"10.1155\/2015\/854015","article-title":"Interactions between CYP3A4 and dietary polyphenols","volume":"2015","author":"Basheer","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/VHRM.S3510","article-title":"Patient adherence and the choice of antihypertensive drugs: Focus on lercanidipine","volume":"4","author":"Pruijm","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Cyclosporine A: Chemistry and Toxicity\u2014A Review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e020192","DOI":"10.1136\/bmjopen-2017-020192","article-title":"Study protocol: Efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): A randomised prospective open-label trial with blinded outcome assessment","volume":"8","author":"Oosterhaven","year":"2018","journal-title":"BMJ Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00007890-199906150-00004","article-title":"The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral and sandimmune. A meta-analysis","volume":"67","author":"Shah","year":"1999","journal-title":"Transplantation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1358\/dot.2008.44.4.1164756","article-title":"Fixed-dose lercanidipine\/enalapril for hypertension","volume":"44","author":"Menne","year":"2008","journal-title":"Drugs Today"},{"key":"ref_79","unstructured":"Napp Pharmaceuticals Ltd (2023, August 14). Zanidip Tablets: SPC from the eMC. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/191\/smpc#gref."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: Human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2003.01833.x","article-title":"The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6","volume":"56","author":"Prueksaritanont","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/TCRM.S55512","article-title":"Pharmacokinetic drug\u2013drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: Factors determining interaction strength and relevant clinical risk management","volume":"10","author":"Zhou","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s43440-020-00058-6","article-title":"Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders","volume":"72","author":"Siwek","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/96286","article-title":"Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders","volume":"53","author":"Siwek","year":"2019","journal-title":"Psychiatr. Polska"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.fjc.0000196241.96759.71","article-title":"Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension","volume":"47","author":"Martinez","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/hr.2016.85","article-title":"Dihydropyridine calcium channel blockers and renal disease","volume":"40","author":"Robles","year":"2016","journal-title":"Hypertens. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2008.10.007","article-title":"Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats","volume":"599","author":"Martinez","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08860220701856946","article-title":"Calcium antagonists and renal failure progression","volume":"30","author":"Robles","year":"2008","journal-title":"Ren. Fail."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00005344-200201000-00005","article-title":"Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats","volume":"39","author":"Sabbatini","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_90","first-page":"948","article-title":"Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats","volume":"294","author":"Sabbatini","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/hh1901.097126","article-title":"Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels","volume":"89","author":"Hansen","year":"2001","journal-title":"Circ. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072054","article-title":"Role of actions of calcium antagonists on efferent arterioles\u2014With special references to glomerular hypertension","volume":"23","author":"Hayashi","year":"2003","journal-title":"Am. J. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/1573402110666140131160617","article-title":"Renal microcirculation and calcium channel subtypes","volume":"9","author":"Homma","year":"2014","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1573402110666140131155331","article-title":"L-\/N-type calcium channel blockers and proteinuria","volume":"9","author":"Ando","year":"2014","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/01.HYP.34.4.673","article-title":"Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats","volume":"34","author":"Karam","year":"1999","journal-title":"Hypertension"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1053\/ajkd.2001.29227","article-title":"Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats","volume":"38","author":"Baylis","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00380-008-1125-y","article-title":"Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease","volume":"24","author":"Omae","year":"2009","journal-title":"Heart Vessel"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1185\/03007995.2013.842891","article-title":"Renal protection with calcium antagonists: The role of lercanidipine","volume":"29","author":"Burnier","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.phrs.2008.09.015","article-title":"Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1\/2 signaling","volume":"59","author":"Wu","year":"2009","journal-title":"Pharmacol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1096\/fj.05-4087fje","article-title":"Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers","volume":"20","author":"Menne","year":"2006","journal-title":"FASEB J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1074248407300621","article-title":"Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats","volume":"12","author":"Rosenthal","year":"2007","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_102","first-page":"136","article-title":"Oxygen-free radical decrease in hypertensive patients treated with lercanidipine","volume":"20","author":"Incandela","year":"2001","journal-title":"Int. Angiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1067\/mcp.2002.127110","article-title":"Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: A randomized, prospective crossover study","volume":"72","author":"Rachmani","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.HYP.0000063361.70525.3C","article-title":"Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension","volume":"41","author":"Taddei","year":"2003","journal-title":"Hypertension"},{"key":"ref_105","first-page":"S17","article-title":"Calcium antagonists and renal protection: Emerging perspectives","volume":"16","author":"Epstein","year":"1998","journal-title":"J. Hypertens. Suppl."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1096\/fasebj.11.2.9039953","article-title":"An essential role for free radicals and derived species in signal transduction","volume":"11","author":"Lander","year":"1997","journal-title":"FASEB J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.numecd.2005.05.003","article-title":"A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress","volume":"15","author":"Stewart","year":"2005","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/01.fjc.0000139448.56713.3d","article-title":"In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages","volume":"44","author":"Canavesi","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"I76","DOI":"10.1161\/01.HYP.15.2_Suppl.I76","article-title":"Inhibition of human mesangial cell proliferation by calcium channel blockers","volume":"15","author":"Shultz","year":"1990","journal-title":"Hypertension"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ki.1988.87","article-title":"Focal and segmental glomerulosclerosis: Analogies to atherosclerosis","volume":"33","author":"Diamond","year":"1988","journal-title":"Kidney Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(85)90076-2","article-title":"Glomerular mesangium: Its function and relationship to angiotensin II","volume":"79","author":"Raij","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_112","first-page":"S13","article-title":"Interactions of the endothelium and mesangium in glomerular injury","volume":"3","author":"Sweeney","year":"1990","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.1996.120","article-title":"Inhibitory effect of calcium channel blockers on human mesangial cell growth: Evidence for actions independent of L-type Ca2+ channels","volume":"49","author":"Orth","year":"1996","journal-title":"Kidney Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000045633","article-title":"Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: Possible mechanism of suppression of AP-1 and CREB activities","volume":"85","author":"Sugiura","year":"2000","journal-title":"Nephron"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000065266","article-title":"Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases","volume":"22","author":"Ono","year":"2002","journal-title":"Am. J. Nephrol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.89.9.4071","article-title":"Manidipine regulates the transcription of cytokine genes","volume":"89","author":"Roth","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/00004872-199611000-00001","article-title":"Blood pressure and renal function: Therapeutic implications","volume":"14","author":"Ruilope","year":"1996","journal-title":"J. Hypertens."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.CIR.99.19.2523","article-title":"Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C","volume":"99","author":"Hempel","year":"1999","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1161\/01.CIR.0000101924.04515.2E","article-title":"Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence","volume":"108","author":"Dayoub","year":"2003","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"13527","DOI":"10.1073\/pnas.212269799","article-title":"S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase","volume":"99","author":"Leiper","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2337\/diabetes.53.8.2101","article-title":"Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-\u03b1\u2014Deficient diabetic mice","volume":"53","author":"Menne","year":"2004","journal-title":"Diabetes"},{"key":"ref_122","first-page":"85","article-title":"Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients","volume":"32","author":"Farah","year":"2013","journal-title":"Int. Angiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/00004872-199917121-00009","article-title":"Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-\u03b1 on endothelial cells","volume":"17","author":"Cominacini","year":"1999","journal-title":"J. Hypertens."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1472-8206.2004.00236.x","article-title":"The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists","volume":"18","author":"Nap","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.HYP.0000058003.27729.5A","article-title":"Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension","volume":"41","author":"Grassi","year":"2003","journal-title":"Hypertension"},{"key":"ref_126","first-page":"S457","article-title":"Endothelial dysfunction in hypertension. The role of natriuretic peptides and endothelin","volume":"4","author":"Barylski","year":"2005","journal-title":"Kardiol Pol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCRESAHA.116.303604","article-title":"The sympathetic nervous system alterations in human hypertension","volume":"116","author":"Grassi","year":"2015","journal-title":"Circ. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1742-1241.2008.01736.x","article-title":"High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: Results from the TOLERANCE study","volume":"62","author":"Barrios","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00005344-200207000-00016","article-title":"Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension","volume":"40","author":"Viviani","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00045391-200209000-00013","article-title":"A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: Effects on myocardial ischemia and heart rate variability","volume":"9","author":"Acanfora","year":"2002","journal-title":"Am. J. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/ndt\/12.11.2244","article-title":"Preservation of renal function: The spectrum of effects by calcium-channel blockers","volume":"12","author":"Tarif","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003495-199957050-00002","article-title":"Renal protection and antihypertensive: Current status drugs","volume":"57","author":"Salvetti","year":"1999","journal-title":"Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.clinthera.2009.08.010","article-title":"Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers","volume":"31","author":"Ferrari","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate\u2014A meta-analysis of randomized trials","volume":"29","author":"Makani","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/03007995.2017.1307817","article-title":"Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: A nationwide cohort study","volume":"33","author":"Cheng","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","article-title":"Effects of \u03b2 blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke","volume":"9","author":"Rothwell","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.611566","article-title":"Effect of dose and combination of antihypertensives on interindividual blood pressure variability: A systematic review","volume":"42","author":"Webb","year":"2011","journal-title":"Stroke"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/jcpt.12139","article-title":"Effects of enalapril\/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients","volume":"39","author":"Derosa","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.all.0000136759.43571.7f","article-title":"Cough and angioedema from angiotensin-converting enzyme inhibitors: New insights into mechanisms and management","volume":"4","author":"Dykewicz","year":"2004","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/HJH.0000000000000239","article-title":"Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: A European randomized, controlled clinical trial","volume":"32","author":"Mancia","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/HJH.0000000000000767","article-title":"Effects of the lercanidipine\u2013enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: Evidence from a large database","volume":"34","author":"Mancia","year":"2016","journal-title":"J. Hypertens."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.jhh.1002248","article-title":"Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: Placebo-controlled, randomized, crossover study with four ABPM","volume":"21","author":"Puig","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1185\/03007995.2014.960072","article-title":"Efficacy and safety evaluation of perindopril\u2013lercanidipine combined therapy in patients with mild essential hypertension","volume":"31","author":"Yang","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_145","unstructured":"Mirabito Colafella, K.M., Uijl, E., and Danser, J. (2018). Reference Module in Biomedical Sciences: Encyclopedia of Endocrine Diseases, Elsevier. [2nd ed.]."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.jhh.1001430","article-title":"A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension","volume":"16","author":"James","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.clinthera.2015.05.512","article-title":"Evaluation of the Efficacy and Safety of the Lercanidipine\/Valsartan Combination in Korean Patients with Essential Hypertension Not Adequately Controlled with Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial","volume":"37","author":"Na","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3122\/jabfm.2013.05.130048","article-title":"Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: A Distributed Ambulatory Research In Therapeutics Network (DARTNet) study","volume":"26","author":"Bronsert","year":"2013","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S23232","article-title":"Fixed combination of lercanidipine and enalapril in the management of hypertension: Focus on patient preference and adherence","volume":"6","author":"Borghi","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12325-008-0042-x","article-title":"Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine","volume":"25","author":"Ferri","year":"2008","journal-title":"Adv. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","article-title":"Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension","volume":"29","author":"Philipp","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vph.2015.06.004","article-title":"Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome","volume":"92","author":"Ghiadoni","year":"2017","journal-title":"Vasc. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03007995.2016.1218839","article-title":"Differential effects of lercanidipine\/enalapril versus amlodipine\/enalapril and hydrochlorothiazide\/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects","volume":"32","author":"Tsioufis","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/03007995.2016.1218838","article-title":"Lercanidipine valuable effect on urine protein losses: The RED LEVEL study","volume":"32","author":"Robles","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40292-020-00358-1","article-title":"PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease","volume":"27","author":"Fici","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"19","DOI":"10.56782\/pps.35","article-title":"Flozins in heart failure\u2014A new reimbursement indication","volume":"20","author":"Olszewski","year":"2022","journal-title":"Prospect. Pharm. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E., Ciszek-Chwalba, A., Jache\u0107, W., and Wojciechowska, C. (2023). The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress\u2014Role of New Drugs, Flozins. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082236"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5603\/EP.a2021.0098","article-title":"Flozins\u2014In the light of the latest recommendations","volume":"72","author":"Rokicka","year":"2021","journal-title":"Endokrynol. Polska"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/nep.13839","article-title":"Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors","volume":"26","author":"Scholtes","year":"2020","journal-title":"Nephrology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.kint.2019.03.032","article-title":"SGLT2 inhibitors\u2019 interaction with other renoactive drugs in type 2 diabetes patients: Still a lot to learn","volume":"96","author":"Scholtes","year":"2019","journal-title":"Kidney Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:50:22Z","timestamp":1760129422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":161,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241814048"],"URL":"https:\/\/doi.org\/10.3390\/ijms241814048","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}